Aureus Licenses AurSCOPE® GPCR to Euroscreen
News Oct 07, 2005
Aureus Pharma has announced that Euroscreen, SA has become a customer of its AurSCOPE GPCR knowledge database.
AurSCOPE GPCR is designed to provide researchers rapid access to quantitative biological activity data mined from the scientific journals and patents for all known GPCR's, a major class of membrane proteins.
Euroscreen will use Aureus Pharma's technology in conjunction with their in-house technology to identify GPCR drug candidates.
“By integrating the Aureus GPCR knowledge database with Euroscreen's research platform, our scientists will be able to rapidly prioritize candidates in lead generation and optimization programs,” said Dr. Francois Roman, Vice President R & D for Euroscreen.
“The information contained within the database will also help us in the design of our chemical libraries for our screening campaigns,” said Dr. Frederic Ooms, Head of Chemistry for Euroscreen.
“As Euroscreen is a world leader in GPCR research, we are pleased they have adopted our AurSCOPE GPCR knowledge base,” said Dr. Andre Michel, CEO of Aureus Pharma.
“AurSCOPE GPCR with its high quality biological and chemical information will complement Euroscreen's technology resulting in an overall acceleration of the discovery process.”
Modified Form of Botox Could Replace Opioids as Treatment for Chronic PainNews
A modified form of botulinum toxin gives long-lasting pain relief in mice without adverse effects and, in time, could replace opioid drugs as a safe and effective way of treating chronic pain, according to new research.READ MORE
Key Ingredient in Diabetes Drug Modified to Improve Side EffectsNews
Improved medications for Type 2 diabetes are one step closer thanks to a new discovery reported this week. By modifying the key ingredient in current diabetes drugs, the researchers produced a compound that was effective for hyperglycemia in animal trials, yet without the most problematic side effects of current drugs.READ MORE
Tackling Cancer at Ground Zero: Designer Molecule Inhibits Protein TargetNews
A new molecule designed by University of Adelaide researchers shows great promise for future treatment of many cancers. The new molecule successfully targets a protein that plays a major role in the growth of most cancers.READ MORE
5th edition of the International Conference Clinical Oncology and Molecular Diagnostics
Jun 17 - Jun 18, 2019